In brief
The CEOs of Pfizer and Johnson & Johnson argue that the speed of COVID-19 vaccine development came from unusual collaboration among companies, governments and academia. They say the world needs several vaccine technologies and manufacturing sources, not one winner. They also argue that transparency, global coordination and sustained investment in public health are what will prepare the world for the next pandemic.
The central tension is speed versus trust. Both executives describe building manufacturing and logistics before knowing whether the vaccines would work, while stressing that safety standards were not compromised. Gorsky says the effort must reach diverse populations and about seven billion people. Bourla and Gorsky both say the pandemic exposed weak global preparedness and that the lessons must be turned into permanent systems.
Questions
Why did Pfizer start making vaccine doses before it knew the vaccine worked?
Bourla says waiting to prove the product before manufacturing would have been too slow. Pfizer ordered equipment and prepared lines as if success were certain.
How many doses did Pfizer expect to make, and how many people is that?
Bourla says Pfizer would make about 50 million doses in December and could ramp up to 1.3 billion doses. Because the vaccine takes two doses, that protects about 650 million people.
What is the difference between Pfizer's vaccine and Johnson & Johnson's?
Gorsky says Pfizer and Moderna use an mRNA approach, while J&J uses a vector approach. He adds that different vaccines may differ in how fast protection starts and how long it lasts.
How can a vaccine that must be kept at minus 70 degrees be shipped around the world?
Bourla says Pfizer engineers built an insulated box about the size of a suitcase that holds 1,000 to 5,000 doses. It has GPS and a thermometer and can travel on normal transport.
What do the CEOs say the world should change before the next pandemic?
Bourla says countries must cooperate, support innovation and keep a strong private sector, and that WHO should be reformed but not abandoned. Gorsky adds that public health systems need investment in resilience, not just efficiency.
Facts
Stated by the speakers. Each quote matches the transcript, which shows what was said, not that it is true.
Albert Bourla says Pfizer is one of the world's biggest suppliers of injectable medicines to hospitals, providing more than a billion units per year.
“We are one of the biggest providers of injectables to hospitals in the world. We are providing one point something billion units every year in the world.”
0:04:20 · Albert Bourla · Hospital supply · 2020
Pfizer already had an agreement with BioNTech to develop mRNA technology, working on a flu vaccine, before they began their COVID-19 vaccine collaboration.
“we had already an agreement with BioNTech to work on this technology, and we were working with them on a flu vaccine.”
0:05:25 · Albert Bourla · mRNA partnership · 2020
Pfizer's first shipment of finished vaccine left its Belgium manufacturing site for the United Kingdom, the first country to approve the product, within hours of approval.
“The first truck of finished goods left our Belgium manufacturing site and crossed the channel and drove to UK, which was the first country that approved the product, hours actually after the approval.”
0:07:10 · Albert Bourla · First shipment · 2020
Because Pfizer's vaccine requires two doses, 1.3 billion doses would protect 650 million people.
“This is a two-dose vaccine, which means that 1.3 billion doses will provide protection to 650 million people.”
0:07:36 · Albert Bourla · Vaccine dosing · 2020
Pfizer's COVID-19 vaccine had to be kept at minus 70 degrees Celsius before use.
“We had, in addition, to deal with the fact that our product needed to maintain in minus 70 degrees Celsius before it's going to be used in people.”
0:17:06 · Albert Bourla · Cold chain · 2020
Pfizer engineers developed a suitcase-sized insulated shipping box carrying 1,000 to 5,000 vaccine doses with GPS and a thermometer.
“It is an isothermic box that can carry the size of a suitcase can carry from 1 ,000 to 5 ,000 doses and is equipped with GPS and the thermometer.”
0:17:37 · Albert Bourla · Vaccine shipping · 2020
Pfizer worked with the US Army and General Gustave Perna, who handled army logistics, on vaccine distribution.
“We are working particularly with the US Army and General Perna, who is responsible for the logistics of the army, and he's very, very knowledgeable about logistics.”
0:18:14 · Albert Bourla · Vaccine logistics · 2020
Albert Bourla says the World Health Organization needs reform but countries should not leave it.
“I think WHO needs to be reformed, but we should never get out from WHO.”
0:24:09 · Albert Bourla · WHO reform · 2020
Albert Bourla says Alex Gorsky once served in the U.S. military at a base in Greece.
“Alex used to serve in the U.S. military and he was serving in a U.S. base in Greece.”
0:02:03 · Albert Bourla · Military service
Alex Gorsky says Johnson & Johnson's vaccine manufacturing builds on a technology called PER.C6, developed more than a decade earlier.
“And more than a decade ago, there was a technology called Percy6 that utilized a different kind of protein and biology in the production of vaccines.”
0:15:32 · Alex Gorsky · Vaccine technology
Alex Gorsky said Johnson & Johnson expected to provide hundreds of millions of vaccine doses in the first half of 2021 if its trials succeeded.
“now we're in a position where we feel confident that in the first half of 2021, we should be able to provide hundreds of millions of doses.”
0:16:01 · Alex Gorsky · Dose forecast · 2021
Alex Gorsky says earlier experience with SARS and Zika did not progress as far as the COVID-19 vaccine effort.
“We had had experiences with SARS and Zika that didn't go in near the direction that we've seen here.”
0:08:54 · Alex Gorsky · Prior outbreaks
Alex Gorsky says Johnson & Johnson's earliest COVID-19 interest centered on its antiviral drugs before turning to a vector-based vaccine.
“And the early interest within Janssen and Johnson & Johnson was more around our antiviral portfolio.”
0:08:54 · Alex Gorsky · Early strategy · 2020
Alex Gorsky says Pfizer and Moderna use an mRNA approach while Johnson & Johnson uses a vector approach.
“We know Pfizer and Moderna has taken an mRNA approach, we're utilizing a vector approach.”
0:20:40 · Alex Gorsky · Vaccine platforms · 2020
Alex Gorsky says research heads at Johnson & Johnson and Pfizer joined regular joint calls with US health leaders during the pandemic.
“Paul Stoffels, our head of research and development, is talking to Mikhail Dolstein, who's heading R &D for Pfizer, where they're on a joint phone call on Saturday morning”
0:12:47 · Alex Gorsky · Industry collaboration · 2020
Alex Gorsky says vaccinating about seven billion people would be unprecedented in world history.
“One of the issues we've been looking at is the distribution reaching 7 billion people. We've never done that in the world's history.”
0:21:18 · Alex Gorsky · Global distribution · 2020
Alex Gorsky says global vaccine access efforts involved developed countries along with Gavi, CEPI and the Bill and Melinda Gates Foundation.
“We're seeing good collaboration among the developed countries, but also with Gavi, with CEPI, with the Bill and Melinda Gates Foundation and others”
0:22:11 · Alex Gorsky · Global access · 2020
Mike Milken says he received his polio vaccination in 1955.
“It was 1955 when I got my polio vaccination.”
0:18:53 · Mike Milken · Polio vaccine · 1955